These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 9026943)
1. [The use of serpens for treating patients with benign prostatic hyperplasia]. Mazo EB; Chekhonin VP; Riabukhin IA; Grigor'ev ME Ter Arkh; 1996; 68(10):47-9. PubMed ID: 9026943 [TBL] [Abstract][Full Text] [Related]
2. [The treatment of patients with benign prostatic hyperplasia with Proscar MSD (finasteride)]. Stepanov VN; Teodorovich OV; Seregin AV; Kadyrov ZA Urol Nefrol (Mosk); 1995; (5):28-30. PubMed ID: 8571480 [TBL] [Abstract][Full Text] [Related]
3. [Changes in the levels of prostate-specific antigen and its molecular forms with alpha 1-antichymotrypsin in patients with benign prostatic hyperplasia]. Grigor'ev ME; Mazo EB; Chekhonin VP Urol Nefrol (Mosk); 1998; (4):33-7. PubMed ID: 9727319 [TBL] [Abstract][Full Text] [Related]
5. [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study]. Fujimoto K; Hirao Y; Ohashi Y; Shibata Y; Fuji K; Tsuji H; Shimizu N; Miyazawa K; Nagata M; Ohtani N; Furuya R; Boku E Hinyokika Kiyo; 2011 Apr; 57(4):177-83. PubMed ID: 21646847 [TBL] [Abstract][Full Text] [Related]
6. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Keetch DW; Andriole GL; Ratliff TL; Catalona WJ Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721 [TBL] [Abstract][Full Text] [Related]
7. [Flutamide, an alternative for patients with benign prostatic hyperplasia (BPH) that cannot be treated with surgery]. Granados EA Arch Esp Urol; 1998 Sep; 51(7):675-9. PubMed ID: 9807893 [TBL] [Abstract][Full Text] [Related]
8. [Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)]. Loran OB; Rasner PI; Kosko D; Pushkar' DIu Urologiia; 2001; (1):8-10. PubMed ID: 11233234 [TBL] [Abstract][Full Text] [Related]
9. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia]. Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528 [TBL] [Abstract][Full Text] [Related]
10. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia. Noguchi K; Suzuki K; Teranishi J; Kondo K; Kishida T; Saito K; Uemura H; Kubota Y Hinyokika Kiyo; 2006 Jul; 52(7):527-30. PubMed ID: 16910584 [TBL] [Abstract][Full Text] [Related]
11. [A clinical analysis of benign prostatic hyperplasia with chronic prostatitis]. Wu XJ; Yang LY; Zhang XZ Zhonghua Nan Ke Xue; 2008 Jun; 14(6):527-9. PubMed ID: 18649752 [TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Ho PJ; Baxter RC Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044 [TBL] [Abstract][Full Text] [Related]
13. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042 [TBL] [Abstract][Full Text] [Related]
14. [The course and limitation of medical treatment for benign prostatic hyperplasia]. Kitagawa N; Akakura K; Akimoto S; Shimazaki J; Murakami S; Ishikawa T; Kataumi S; Sotoma T; Takagishi H; Kitamura Y Hinyokika Kiyo; 1994 Sep; 40(9):781-8. PubMed ID: 7528462 [TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. Andriole GL; Marberger M; Roehrborn CG J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723 [TBL] [Abstract][Full Text] [Related]
16. [Combined use of 5 alpha-reductase inhibitors and alpha-l adrenergic receptor blockers in patients with benign prostatic hyperplasia]. Tkachuk VN; Al'-Shukri SKh; Luk'ianov AE; Kornienko VI; Kuz'min IV Urol Nefrol (Mosk); 1998; (3):5-8. PubMed ID: 9644979 [TBL] [Abstract][Full Text] [Related]
17. [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis]. Shaplygin LV; Sivakov AA Urologiia; 2007; (3):35-7, 39. PubMed ID: 17722618 [TBL] [Abstract][Full Text] [Related]
18. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia. Malkowicz SB; McKenna WG; Vaughn DJ; Wan XS; Propert KJ; Rockwell K; Marks SH; Wein AJ; Kennedy AR Prostate; 2001 Jun; 48(1):16-28. PubMed ID: 11391683 [TBL] [Abstract][Full Text] [Related]
19. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia]. Tkachuk VN; Al'-Shukri SKh; Kornienko VI; Kuz'min IV Urol Nefrol (Mosk); 1998; (4):37-9. PubMed ID: 9727320 [TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Ho PJ; Baxter RC Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]